Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement

• Ngā kaituhi matua: Zhidi Pan (Author), Jie Chen (Author), Xiaodong Xiao (Author), Yueqing Xie (Author), Hua Jiang (Author), Baohong Zhang (Author), Huili Lu (Author), Yunsheng Yuan (Author), Lei Han (Author), Yuexian Zhou (Author), Huifang Zong (Author), Lei Wang (Author), Rui Sun (Author), Jianwei Zhu (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2022-04-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

T cell engaging bispecific antibody (TCB) is an effective immunotherapy for cancer treatment. Through co-targeting CD3 and tumor-associated antigen (TAA), TCB can redirect CD3+ T cells to eliminate tumor cells regardless of the specificity of T cell receptor. Tissue factor (TF) is a TAA that involve...